Phosphodiesterase 4 as a candidate therapeutic target of cancer

Authors

  • Arka Bagchi 1Molecular Cell Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani, Nadia-741 235, West Bengal, India & 2Department of Biological Sciences, BITS Pillani - K K Birla Goa Campus, Goa-403 726, India
  • Arunima Biswas 1Molecular Cell Biology Laboratory, Department of Zoology, University of Kalyani, Kalyani, Nadia-741 235, West Bengal, India

DOI:

https://doi.org/10.56042/ijbb.v62i3.13103

Keywords:

cAMP, Cancer progression, Inhibitors, Metastasis, Phosphodiesterase 4, Roflumilast, Rolipram

Abstract

In this review, we explore the potential of cAMP-Phosphodiesterase 4 (PDE4), a key intracellular enzyme, as a therapeutic target for cancer treatment. cAMP-PDEs play a critical role in regulating intracellular levels of cyclic adenosine monophosphate (cAMP), an essential second messenger involved in cell proliferation and metastasis in a tissue-specific manner depending on the PDE isoforms present. Elevated PDE4 expression has been reported in cancers such as breast, cervical, and lung cancer. Specific PDE4 subtypes are recognized for their roles in cancer progression, making PDE4 inhibitors promising candidates for therapeutic intervention. This review examines the role of PDE4 in cancer progression and highlights the therapeutic potential of studied PDE4 inhibitors.

Downloads

Published

2025-02-06

Issue

Section

Review

How to Cite

Phosphodiesterase 4 as a candidate therapeutic target of cancer. (2025). Indian Journal of Biochemistry and Biophysics (IJBB), 62(3), 213-221. https://doi.org/10.56042/ijbb.v62i3.13103

Similar Articles

1-10 of 176

You may also start an advanced similarity search for this article.